Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST: Simplifying Treatment in Children with Bone and Joint Infections
NCT04538053Phase 4Recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Jun 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of cefalexin in Bone and osteoarticular infections (BJI), osteomyelitis (OM) and septic arthritis (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Proportion of children assessed as having made a full recovery at 3 months. Started Jun 2021; status: recruiting.
02
Drugs
cefalexin
03
Conditions
Bone and osteoarticular infections (BJI)osteomyelitis (OM)septic arthritis
Beyond the preview
Go deeper on NCT04538053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538053.